HY-138314 Search Results


p2y 1  (MedChemExpress)
90
MedChemExpress p2y 1
Inhibition of AsPC-1 cell-mediated platelet aggregation. Representative aggregation curves of platelets activated with 1×10 4 AsPC-1 cells/mL (black curves), or platelets preincubated with inhibitors for TXA2 receptor, TLR4, SYK tyrosine kinase, purinergic receptors <t>P2Y</t> 12 , P2Y 1 , P2X 1 , GPVI, GPIIbIIIa, P-selectin, thrombin, or factor Xa, respectively (red curves) ( n = 5). Effects of the different inhibitors on platelet aggregation are shown as ratio of time to half-maximal aggregation of treated versus untreated platelets.
P2y 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p2y 1/product/MedChemExpress
Average 90 stars, based on 1 article reviews
p2y 1 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Inhibition of AsPC-1 cell-mediated platelet aggregation. Representative aggregation curves of platelets activated with 1×10 4 AsPC-1 cells/mL (black curves), or platelets preincubated with inhibitors for TXA2 receptor, TLR4, SYK tyrosine kinase, purinergic receptors P2Y 12 , P2Y 1 , P2X 1 , GPVI, GPIIbIIIa, P-selectin, thrombin, or factor Xa, respectively (red curves) ( n = 5). Effects of the different inhibitors on platelet aggregation are shown as ratio of time to half-maximal aggregation of treated versus untreated platelets.

Journal: International Journal of Molecular Sciences

Article Title: A Combined Activity of Thrombin and P-Selectin Is Essential for Platelet Activation by Pancreatic Cancer Cells

doi: 10.3390/ijms22073323

Figure Lengend Snippet: Inhibition of AsPC-1 cell-mediated platelet aggregation. Representative aggregation curves of platelets activated with 1×10 4 AsPC-1 cells/mL (black curves), or platelets preincubated with inhibitors for TXA2 receptor, TLR4, SYK tyrosine kinase, purinergic receptors P2Y 12 , P2Y 1 , P2X 1 , GPVI, GPIIbIIIa, P-selectin, thrombin, or factor Xa, respectively (red curves) ( n = 5). Effects of the different inhibitors on platelet aggregation are shown as ratio of time to half-maximal aggregation of treated versus untreated platelets.

Article Snippet: In some experiments, prior to activation, platelets were preincubated with inhibitors against GPVI (Losartan, 20 µM, Biotechne, Wiesbaden-Nordenstadt, Germany), TXA2 (Seratrodast, 10 µg/mL, MedChem Express, Hycultec GmbH, Beutelsbach, Germany), TLR4 (TAK-242, 5 µM, MedChem Express), Syk (BAY61-3606, 10 µM, Santa Cruz Biotechnology, Heidelberg, Germany), GPIIbIIIa (Eptifibatide, 10 µg/mL, MedChem Express), purinergic receptors P2Y 12 (Ticagrelor, 1 µM), P2Y 1 (BPTU, 10 µM), P2X 1 (PSB-18164, 10 µM) (were kindly provided by Prof. Dr. Christa E. Müller, Pharmaceutical Institute, University of Bonn), factor Xa (Rivaroxaban, 0.5 nM, MedChem Express), and thrombin (Argatroban, 10 µM, MedChem Express), respectively.

Techniques: Inhibition

Inhibition of AsPC-1 cell induced platelet dense granule secretion. Quantification of ATP release from resting platelets, platelets co-incubated with 1 × 10 4 AsPC-1 cells, or platelets activated with TRAP-6, respectively, after 20 min. In some experiments platelets were preincubated with inhibitors for TXA2 receptor, TLR4, SYK tyrosine kinase, purinergic receptors P2Y 12 , P2X 1, P2Y 1 , GPVI, GPIIbIIIa, P-selectin, thrombin, or factor Xa, respectively, before the addition of AsPC-1 cells. Data are means of n = 3–5 (±SD), asterisks indicate statistical significance: * p < 0.05; *** p < 0.001.

Journal: International Journal of Molecular Sciences

Article Title: A Combined Activity of Thrombin and P-Selectin Is Essential for Platelet Activation by Pancreatic Cancer Cells

doi: 10.3390/ijms22073323

Figure Lengend Snippet: Inhibition of AsPC-1 cell induced platelet dense granule secretion. Quantification of ATP release from resting platelets, platelets co-incubated with 1 × 10 4 AsPC-1 cells, or platelets activated with TRAP-6, respectively, after 20 min. In some experiments platelets were preincubated with inhibitors for TXA2 receptor, TLR4, SYK tyrosine kinase, purinergic receptors P2Y 12 , P2X 1, P2Y 1 , GPVI, GPIIbIIIa, P-selectin, thrombin, or factor Xa, respectively, before the addition of AsPC-1 cells. Data are means of n = 3–5 (±SD), asterisks indicate statistical significance: * p < 0.05; *** p < 0.001.

Article Snippet: In some experiments, prior to activation, platelets were preincubated with inhibitors against GPVI (Losartan, 20 µM, Biotechne, Wiesbaden-Nordenstadt, Germany), TXA2 (Seratrodast, 10 µg/mL, MedChem Express, Hycultec GmbH, Beutelsbach, Germany), TLR4 (TAK-242, 5 µM, MedChem Express), Syk (BAY61-3606, 10 µM, Santa Cruz Biotechnology, Heidelberg, Germany), GPIIbIIIa (Eptifibatide, 10 µg/mL, MedChem Express), purinergic receptors P2Y 12 (Ticagrelor, 1 µM), P2Y 1 (BPTU, 10 µM), P2X 1 (PSB-18164, 10 µM) (were kindly provided by Prof. Dr. Christa E. Müller, Pharmaceutical Institute, University of Bonn), factor Xa (Rivaroxaban, 0.5 nM, MedChem Express), and thrombin (Argatroban, 10 µM, MedChem Express), respectively.

Techniques: Inhibition, Incubation